LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$1.82
· of 52w range
· above low
· to high
$1.1152w low
$2.6852w high
Market Cap (MRQ)
$813M
P/E (TTM)
-12.1
EPS (TTM)
$-0.15
Revenue (TTM)
$41M
your badges
52W Range
$1–$3
Analyst Rating
BUY
Price Target
$5
P/E
-12.1
ROE
-40.2%
Net Profit Margin
-147.4%
Your badge strip is empty — pin a metric anywhere on this page.
LXRX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.82
Market Cap (MRQ)
$813M
P/E (TTM)
-12.1
EPS (TTM)
$-0.15
Revenue (TTM)
$41M
ROE (TTM)
-40.2%
Debt/Equity (MRQ)
0.3
52W Range
$1–$3
LXRX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| May 21, 2015 | 1-for-7 | Reverse |
About Lexicon Pharmaceuticals, Inc. - Common Stock Company overview from Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of different compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryPharmaceuticals
employees81
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$50M2016-12-31 → 2025-12-31
EPS$-0.142017-12-31 → 2025-12-31
Free Cash Flow$-68M2016-12-31 → 2025-12-31
Net margin-147.4%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | LXRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | -12.15Y avg ≈-4.2 | ≈-4.2 | · | · | |
| P/S (TTM) | 19.65Y avg ≈1530.9 | ≈1530.9 | 6.6 | Overvalued | |
| P/B (MRQ) | 4.75Y avg ≈4.1 | ≈4.1 | 3.8 | Overvalued | |
| EV / EBITDA (TTM) | -12.5 | · | · | · | |
| Price / FCF | -9.85Y avg ≈-5.6 | ≈-5.6 | · | · | |
| Price / Cash Flow | -9.85Y avg ≈-5.7 | ≈-5.7 | · | · | |
| EV / Revenue (TTM) | 16.3 | · | · | · | |
| EV / FCF | -9.2 | · | · | · | |
| Price / Tangible Book | 10.65Y avg ≈6.7 | ≈6.7 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | LXRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | -131.4%5Y avg ≈-23342.3% | ≈-23342.3% | -78.2% | Weak | |
| EBITDA Margin (TTM) | -130.3%5Y avg ≈-23251.5% | ≈-23251.5% | -59.5% | Weak | |
| Net Profit Margin (TTM) | -147.4%5Y avg ≈-23649.3% | ≈-23649.3% | -23.7% | Weak | |
| ROA (TTM) | -25.7%5Y avg ≈-58.7% | ≈-58.7% | -34.1% | Top tier | |
| ROE (TTM) | -40.2%5Y avg ≈-105.9% | ≈-105.9% | 50.0% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | LXRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.35Y avg ≈0.6 | ≈0.6 | 0.0 | High debt | |
| Current Ratio (MRQ) | 13.45Y avg ≈5.2 | ≈5.2 | 4.3 | Strong liquidity | |
| Quick Ratio (MRQ) | 13.15Y avg ≈5.1 | ≈5.1 | 2.0 | Strong liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.35Y avg ≈0.7 | ≈0.7 | 0.0 | High debt |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | LXRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 60.2%5Y avg ≈631.2% | ≈631.2% | · | · | |
| Revenue CAGR 3Y | 610.2%5Y avg ≈305.9% | ≈305.9% | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | LXRX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.25Y avg ≈0.1 | ≈0.1 | 0.4 | Weak | |
| Inventory Turnover | 1.15Y avg ≈1.2 | ≈1.2 | 2.1 | Weak | |
| Receivables Turnover | 17.05Y avg ≈8.3 | ≈8.3 | 3.5 | Top tier | |
| Revenue / Employee | ≈$614.9K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
48.2%
Next Report
Nov 13, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 4, 2026 | $-0.07 | $-0.05 | -36.7% |
| March 31, 2026 | May 11, 2026 | $0.00 | $-0.04 | 100.0% |
| Dec. 31, 2025 | $-0.04 | $-0.07 | 43.2% | |
| Sept. 30, 2025 | $-0.04 | $-0.07 | 40.6% | |
| June 30, 2025 | $0.01 | $-0.08 | 112.6% | |
| March 31, 2025 | $-0.07 | $-0.10 | 29.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.29 | · | · | $0.62 | $0.76 | $1.10 | $1.10 | $-0.25 | $0.49 | $1.50 | · | $0.39 | |
| Revenue / Share | $0.14 | $0.10 | $0.01 | · | $0.00 | $0.22 | $2.76 | · | · | · | · | · | |
| Cash Flow / Share | $-0.19 | $-0.56 | $-0.73 | · | $-0.60 | $-1.29 | $0.97 | · | · | · | · | · | |
| Cash / Share | $0.09 | · | · | $0.24 | $0.43 | $0.89 | $0.34 | $0.76 | $0.58 | $0.45 | · | $0.19 | |
| EPS (TTM) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | $-0.12 | $-0.12 | · |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,294,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | · | 363,399,000 | 363,570,000 | 362,073,000 | · | 361,492,000 | 310,836,000 | 245,390,000 | · | 244,925,000 | 204,783,000 | 189,014,000 | · | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | · | · | $-64M | $-55M | $-45M | · | $-50M | · | $-31M | · | $-23M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | · | · | $100M | $99M | $100M | · | $99M | · | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | · | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | · | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | · | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | · | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | · | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | · | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | · | · | -21.7% | -15.5% | -16.7% | · | -21.6% | · | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | · | · | -40.8% | -25.1% | -25.7% | · | -35.6% | · | -35.3% | · | -16.7% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | · | · | 7.5 | 11.5 | 15.6 | · | 6.9 | · | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | · | · | 7.2 | 11.2 | 15.3 | · | 6.8 | · | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | · | · | 0.6 | 0.4 | 0.3 | · | 0.7 | · | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | · | -17.1 | · | -26.7 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | · | · | 0.1 | 0.4 | 0.0 | · | 0.0 | · | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | · | · | 1.1 | 1.0 | 1.3 | · | 0.9 | · | · | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.39 | $0.48 | · | $0.33 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Revenue / Share | $0.00 | $0.05 | · | $0.04 | $0.08 | · | · | $0.00 | $0.01 | $0.00 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | · | $-0.04 | · | · | · | · | · | · | · | $-0.22 | · | · | · | · | · | · | |
| Cash / Share | $0.09 | $0.09 | · | $0.14 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $-0.15 | $-0.07 | · | $-0.18 | $-0.32 | $-0.50 | · | $-0.75 | $-0.78 | $-0.83 | · | $-0.77 | $-0.69 | · | · | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41M | $70M | · | $71M | $58M | $31M | · | $5M | $4M | $2M | · | $531.0K | $408.0K | $126.0K | · | · | |
| Net Income TTM | $-61M | $-26M | · | $-69M | $-121M | $-177M | · | $-216M | $-202M | $-194M | · | $-158M | $-131M | $-110M | · | $-97M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -16.0 | -22.3 | · | -7.5 | -3.0 | -0.9 | · | -2.1 | -2.2 | -2.9 | · | -1.4 | -3.3 | · | · | · | |
| P/S | 25.9 | 9.5 | · | 7.0 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 22.5 | 7.8 | · | 6.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -6.2% | -4.5% | · | -13.3% | -33.7% | -108.7% | · | -47.8% | -46.4% | -34.6% | · | -70.6% | -30.1% | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K |
| Operating Margin % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M |
| Diluted EPS | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 |
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M |
Institutional owners (13F) 167 filers · $890.0M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
167
Value held
$890.0M
New positions
43
Exited positions
27
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 43 (+9 vs prior Q) | 27 (+14 vs prior Q) | 39 (-5 vs prior Q) | 38 (+14 vs prior Q) | +42.4M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Artal Group S.A. | $420,374,549 | 175,156,062 | 47.23% | Shares |
| FMR LLC | $124,276,907 | 51,782,045 | 13.96% | Shares |
| Siren, L.L.C. | $106,328,443 | 44,303,518 | 11.95% | Shares |
| Sessa Capital IM, L.P. | $45,506,006 | 18,960,836 | 5.11% | Shares |
| BlackRock, Inc. | $41,636,978 | 17,348,741 | 4.68% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $23,762,899 | 9,901,208 | 2.67% | Shares |
| Point72 Asset Management, L.P. | $19,803,180 | 8,251,325 | 2.23% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $14,989,739 | 6,244,372 | 1.68% | Shares |
| STATE STREET CORP | $11,802,646 | 4,917,769 | 1.33% | Shares |
| VANGUARD GROUP INC | $11,047,532 | 9,606,549 | 1.24% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5,658,598 | 2,357,749 | 0.64% | Shares |
| NORTHERN TRUST CORP | $4,724,686 | 1,968,619 | 0.53% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4,696,260 | 1,956,775 | 0.53% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $3,922,970 | 1,634,571 | 0.44% | Shares |
| CITADEL ADVISORS LLC | $3,842,837 | 1,601,182 | 0.43% | Shares |
| CIBC Private Wealth Group LLC | $3,240,347 | 2,400,257 | 0.36% | Shares |
| Ishara Investments LP | $3,050,400 | 1,271,000 | 0.34% | Shares |
| MILLENNIUM MANAGEMENT LLC | $2,722,150 | 1,134,229 | 0.31% | Shares |
| RENAISSANCE TECHNOLOGIES LLC | $2,704,800 | 1,127,000 | 0.30% | Shares |
| MACKENZIE FINANCIAL CORP | $2,312,050 | 963,354 | 0.26% | Shares |
| ADAR1 Capital Management, LLC | $1,800,000 | 750,000 | 0.20% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,672,262 | 696,776 | 0.19% | Shares |
| UBS Group AG | $1,643,312 | 684,713 | 0.18% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,604,400 | 668,500 | 0.18% | Call option |
| TWO SIGMA INVESTMENTS, LP | $1,544,266 | 643,444 | 0.17% | Shares |
| Nuveen, LLC | $1,407,994 | 586,664 | 0.16% | Shares |
| JANE STREET GROUP, LLC | $1,398,960 | 582,900 | 0.16% | Call option |
| Bank of New York Mellon Corp | $1,364,893 | 568,706 | 0.15% | Shares |
| Invesco Ltd. | $1,219,370 | 508,071 | 0.14% | Shares |
| GOLDMAN SACHS GROUP INC | $1,165,310 | 485,546 | 0.13% | Shares |
| Compagnie Lombard Odier SCmA | $1,152,000 | 480,000 | 0.13% | Shares |
| BANK OF AMERICA CORP /DE/ | $1,011,117 | 421,299 | 0.11% | Shares |
| BARCLAYS PLC | $929,960 | 387,483 | 0.10% | Shares |
| CITADEL ADVISORS LLC | $886,320 | 369,300 | 0.10% | Call option |
| XTX Topco Ltd | $858,905 | 357,877 | 0.10% | Shares |
| CANADA PENSION PLAN INVESTMENT BOARD | $618,960 | 257,900 | 0.07% | Shares |
| RHUMBLINE ADVISERS | $616,523 | 256,885 | 0.07% | Shares |
| DEUTSCHE BANK AG\ | $594,068 | 247,528 | 0.07% | Shares |
| WELLS FARGO & COMPANY/MN | $553,128 | 230,470 | 0.06% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $431,280 | 179,700 | 0.05% | Shares |
| CITIGROUP INC | $420,492 | 175,205 | 0.05% | Shares |
| GROUP ONE TRADING LLC | $420,031 | 175,013 | 0.05% | Shares |
| Virtus Investment Advisers, LLC | $408,996 | 170,415 | 0.05% | Shares |
| Headlands Technologies LLC | $401,275 | 167,198 | 0.05% | Shares |
| Ikarian Capital, LLC | $395,218 | 164,674 | 0.04% | Shares |
| Quarry LP | $374,846 | 156,186 | 0.04% | Shares |
| MetLife Investment Management, LLC | $351,384 | 146,410 | 0.04% | Shares |
| MORGAN STANLEY | $318,964 | 132,902 | 0.04% | Shares |
| PANAGORA ASSET MANAGEMENT INC | $316,901 | 132,042 | 0.04% | Shares |
| JPMORGAN CHASE & CO | $289,975 | 109,839 | 0.03% | Shares |
Activists & 5%+ owners 11 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 filings | May 8, 2026 | 39.40% | Amendment | · | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 filings | Dec. 9, 2024 | · | Initial filing | · | SEC |
| Feb. 24, 2012 | · | Initial filing | · | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | Dec. 27, 2011 | · | Initial filing | · | SEC |
| Nov. 14, 2011 | · | Initial filing | · | SEC | |
| Aug. 15, 2011 | · | Initial filing | · | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | March 19, 2010 | · | Initial filing | Capital structure | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 filings | Aug. 5, 2005 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | Aug. 8, 2003 | · | Initial filing | · | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | July 18, 2003 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person | March 19, 2003 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 49 insiders · 32 officers · 19 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | Feb. 28, 2026 M | 298,432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | Feb. 28, 2024 M | 1,098,068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | Feb. 28, 2014 M | 1,021,329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | Feb. 28, 2026 M | 105,356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | June 2, 2009 A | · | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | Feb. 7, 2008 A | 50,200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | July 8, 2024 A | 324,214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | Feb. 28, 2026 M | 31,264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | Feb. 28, 2026 M | 150,132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | Feb. 28, 2026 M | 277,945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | Feb. 28, 2026 M | 323,430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | Feb. 28, 2026 M | 93,869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | Feb. 28, 2026 M | 428,802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | Feb. 28, 2025 M | 76,368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | Feb. 28, 2025 M | 339,104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | Feb. 13, 2025 A | · | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | Feb. 28, 2024 M | 162,672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | Feb. 8, 2024 A | · | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | Feb. 28, 2023 M | 53,136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | March 15, 2021 M | 71,766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | April 22, 2020 F | 55,584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | April 22, 2020 F | 85,719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | March 2, 2015 M | 8,235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | Feb. 28, 2014 M | 278,703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | Feb. 15, 2010 A | · | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | Feb. 15, 2010 A | 27,306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | Feb. 7, 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | Feb. 7, 2008 A | 10,200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | Feb. 7, 2008 A | · | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | Feb. 13, 2007 A | · | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | Feb. 23, 2004 M | 15,000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | Jan. 12, 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | Director | June 3, 2026 M | 89,312 | 0 | 0 | $0 |
| Diane E. Sullivan | Director | June 3, 2026 M | 126,122 | 0 | 0 | $0 |
| Judith L Swain | Director | June 3, 2026 M | 174,486 | 0 | 0 | $0 |
| Amouyal Philippe | Director | June 3, 2026 M | 374,486 | 0 | 0 | $0 |
| Sam L Barker | Director | June 3, 2026 M | 213,771 | 0 | 0 | $0 |
| Christopher J Sobecki | Director | June 3, 2026 M | 293,177 | 0 | 0 | $0 |
| Raymond Debbane | Director | June 3, 2026 M | 1,995,498 | 7 | 0 | $723,048 |
| Robert J Lefkowitz MD | Director | May 13, 2024 A | 48,364 | 0 | 0 | $0 |
| Frank Palantoni | Director | May 21, 2023 M | 40,332 | 0 | 0 | $0 |
| Alan S Nies | Director | May 21, 2023 M | 41,046 | 0 | 0 | $0 |
| Invus C.V. | Director | Dec. 31, 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | Director | April 24, 2009 A | · | 0 | 0 | $0 |
| Clayton Stuart Rose | Director | June 26, 2007 P | 25,000 | 0 | 0 | $0 |
| Barry Mills | Director | April 26, 2007 A | 25,000 | 0 | 0 | $0 |
| Patricia M Cloherty | Director | April 27, 2006 A | · | 0 | 0 | $0 |
| Thomas C Caskey | Director | Oct. 13, 2005 P | 6,300 | 0 | 0 | $0 |
| Praveen Tyle | · | Feb. 28, 2021 M | 120,791 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 16 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.81% | 161,882 NS | July 31, 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0.45% | 40,310 NS | July 31, 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.43% | 53,319 SH | Oct. 1, 2026 | Daily |
| IWC · iShares Trust | 0.12% | 842,323 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 266,401 SH | Aug. 19, 2026 | Daily |
| IWO · iShares Trust | 0.03% | 2,343,443 SH | Sept. 11, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 1,432,882 SH | Aug. 19, 2026 | Daily |
| RSSL · Global X Funds | 0.02% | 118,391 NS | July 31, 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 260,485 SH | Sept. 30, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 6,319,224 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 2,594,934 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 637,561 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 17,992 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 85,389 SH | Sept. 3, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 7,083,651 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 20,905 SH | Aug. 19, 2026 | Daily |
LXRX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 11 analysts
BUY
Median target
$4.55
+150.0%
3 27.3%
Strong Buy
5 45.5%
Buy
3 27.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
6 analysts · 2026-09-30Mean target $4.55 +149.8%
← Below all targets
Current price $1.82
Low$2.00
Mean$4.55
High$8.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | · |
| ANRO | $568M | -8.1 | · | · | -46.1% | · |
| ALMS | · | -3.4 | · | -1011.8% | -61.9% | · |
| APMD | · | · | · | · | · | · |
| SGP | · | · | · | · | 50.0% | · |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026